News & Updates
Excerpt from the Press Release: UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment…
Read More
Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migration GP-2250 demonstrated ability to downregulate protein expression of aberrant tumorigenic pathways in virus-negative MCC cell lines Excerpt from the Press Release: BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the…
Read More
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the M ajority of Patients Suggest Preservation of Cardiac Function- -Results in Performance of the Upper Limb PUL v2.0 Continue to Show Long-Term Benefit in Skeletal Muscle Function (p=0.02)- -Safety and Efficacy Results Continue to Suggest Potential Disease Attenuation in Duchenne Muscular Dystrophy (DMD) Excerpt from the…
Read More
The OBIO® Capital Access Advisory Program (CAAP®) operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, working towards Series A financing and strategic partnerships. OBIO’s CAAP® creates high value deal flow for both companies and investors, culminating with a presentation at the OBIO® Investment Summitin 2024. Click the button below to read…
Read More
Data published in the NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI…
Read More
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics’ Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from ENDO President Excerpt from the Press Release: SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023…
Read More
– Combination therapy cohort initiated in Palleon’s ongoing study to evaluate safety, pharmacodynamic effects, and antitumor activity of its lead glyco-immunology candidate in patients with advanced cancer – E-602 being evaluated in combination with cemiplimab (Libtayo®) as part of clinical trial supply agreement with Regeneron Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a…
Read More
At TrialStat, we offer comprehensive medical coding services specifically tailored for clinical trials. Our advanced technology ensures fast and accurate coding of verbatim terms from both our Electronic Data Capture (EDC) system and external sources. With our innovative coding platform, we streamline the coding process, providing efficient and reliable solutions for your clinical research needs.…
Read More
Excerpt from the Press Release: WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate,…
Read More
Phase 2 Data at EULAR Suggested Profervia® Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity Excerpt from the Press Release: BOSTON, June 21, 2023 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral calcium-channel antagonist (CCB) in patients with SSc…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?